Physician profile
Sunit B Desai
NPI 1861496457
$2,114.73
in general payments reported to CMS, 2019-2025
29 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $38.85 · 2021: $160 · 2022: $467 · 2023: $367 · 2024: $230 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $296.24 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $281.29 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $263.90 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $255.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $120.55 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $104.85 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $64.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.39 | 2022-2024 | Jardiance |
| Biogen, INC. | $60.55 | 2019 | |
| Lilly USA, LLC | $59.01 | 2022-2025 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $57.92 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $53.50 | 2023-2024 | Rexulti |
| Lundbeck LLC | $53.32 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $50.24 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.01 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.68 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.17 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $27.62 | 2021-2022 | |
| Amgen INC. | $26.05 | 2022-2023 | Otezla, Repatha |
| Avanir Pharmaceuticals, INC. | $25.07 | 2019 | |
| Abbott Laboratories | $24.97 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $18.89 | 2022 | |
| Ibsa Pharma INC. | $16.50 | 2024 | Licart, Tirosint |
| Kowa Pharmaceuticals America, INC. | $14.83 | 2025 | Zoryve |
| Allergan, INC. | $14.79 | 2019 | |
| Abbvie INC. | $14.72 | 2023 | Vraylar |
| Renalytix Ai, INC. | $13.12 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ucb, INC. | $12.74 | 2019 | |
| Philips North America LLC | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunit Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.